Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17-48. doi: https://doi.org/10.3322/caac.21763.

Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, et al. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2022;63(1):59-68. doi: https://doi.org/10.2967/jnumed.121.263262.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ristau BT, O'Keefe DS, Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol. 2014;32(3):272-9. doi: https://doi.org/10.1016/j.urolonc.2013.09.003.

Article  PubMed  Google Scholar 

Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, et al. Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology. 2021;299(2):248-60. doi: https://doi.org/10.1148/radiol.2021202771.

Article  PubMed  Google Scholar 

Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. J Nucl Med. 2021;62(5):596-604. doi: https://doi.org/10.2967/jnumed.120.257238.

Article  CAS  PubMed  Google Scholar 

Walker SM, Lim I, Lindenberg L, Mena E, Choyke PL, Turkbey B. Positron emission tomography (PET) radiotracers for prostate cancer imaging. Abdom Radiol (NY). 2020;45(7):2165-75. doi: https://doi.org/10.1007/s00261-020-02427-4.

Article  PubMed  Google Scholar 

Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7(5B):927-35.

CAS  PubMed  Google Scholar 

Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, et al. PSMA Ligands for PET Imaging of Prostate Cancer. J Nucl Med. 2017;58(10):1545-52. doi: https://doi.org/10.2967/jnumed.117.191031.

Article  CAS  PubMed  Google Scholar 

Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning M, Oh SW, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2018;26(2):131-46. doi: https://doi.org/10.1530/ERC-18-0226.

Article  PubMed  Google Scholar 

Hope TA, Afshar-Oromieh A, Eiber M, Emmett L, Fendler WP, Lawhn-Heath C, et al. Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. AJR Am J Roentgenol. 2018;211(2):286-94. doi: https://doi.org/10.2214/AJR.18.19957.

Article  PubMed  PubMed Central  Google Scholar 

Meher N, VanBrocklin HF, Wilson DM, Flavell RR. PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer. Pharmaceuticals (Basel). 2023;16(2). doi: https://doi.org/10.3390/ph16020315.

Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, et al. Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). J Urol. 2023:101097ju0000000000003493. doi: https://doi.org/10.1097/ju.0000000000003493.

Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466-86. doi: https://doi.org/10.1007/s00259-022-06089-w.

Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, et al. Multiphasic (68)Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients. J Nucl Med. 2020;61(10):1484-90. doi: https://doi.org/10.2967/jnumed.119.238071.

Article  CAS  PubMed  Google Scholar 

Lawhn-Heath C, Flavell RR, Korenchan DE, Deller T, Lake S, Carroll PR, et al. Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction. Mol Imaging. 2018;17:1536012118811741. doi: https://doi.org/10.1177/1536012118811741.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iravani A, Hofman MS, Mulcahy T, Williams S, Murphy D, Parameswaran BK, et al. (68)Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. Cancer Imaging. 2017;17(1):31. doi: https://doi.org/10.1186/s40644-017-0133-5.

Article  PubMed  PubMed Central  Google Scholar 

Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Schafers M, Bogemann M, et al. Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(12):2055-61. doi: https://doi.org/10.1007/s00259-018-4089-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions. Mol Imaging Biol. 2016;18(3):428-36. doi: https://doi.org/10.1007/s11307-016-0945-x.

Article  CAS  PubMed  Google Scholar 

Sandgren K, Johansson L, Axelsson J, Jonsson J, Ögren M, Ögren M, et al. Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients. EJNMMI Phys. 2019;6(1):2. doi: https://doi.org/10.1186/s40658-018-0239-2.

Article  PubMed  PubMed Central  Google Scholar 

Ghafoor S, Burger IA, Vargas AH. Multimodality Imaging of Prostate Cancer. J Nucl Med. 2019;60(10):1350-8. doi: https://doi.org/10.2967/jnumed.119.228320.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Treglia G, Pereira Mestre R, Ferrari M, Bosetti DG, Pascale M, Oikonomou E, et al. Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis. Am J Nucl Med Mol Imaging. 2019;9(2):127-39.

PubMed  PubMed Central  Google Scholar 

Wang R, Shen G, Huang M, Tian R. The Diagnostic Role of (18)F-Choline, (18)F-Fluciclovine and (18)F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis. Front Oncol. 2021;11:684629. doi: https://doi.org/10.3389/fonc.2021.684629.

Pernthaler B, Kulnik R, Gstettner C, Salamon S, Aigner RM, Kvaternik H. A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT. Clin Nucl Med. 2019;44(10):e566-e73. doi: https://doi.org/10.1097/RLU.0000000000002703.

Article  PubMed  Google Scholar 

Schuster DM, Savir-Baruch B, Nieh PT, Master VA, Halkar RK, Rossi PJ, et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology. 2011;259(3):852-61. doi: https://doi.org/10.1148/radiol.11102023.

Article  PubMed  PubMed Central  Google Scholar 

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286-94. doi: https://doi.org/10.1016/S1470-2045(19)30415-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017;317(24):2532-42. doi: https://doi.org/10.1001/jama.2017.7248.

Article  PubMed  Google Scholar 

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(5):479-505. doi: https://doi.org/10.6004/jnccn.2019.0023.

Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021;7(11):1635-42. doi: https://doi.org/10.1001/jamaoncol.2021.3771.

Article  PubMed  PubMed Central  Google Scholar 

Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with (18)F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol. 2021;206(1):52-61. doi: https://doi.org/10.1097/JU.0000000000001698.

Article  PubMed  PubMed Central  Google Scholar 

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-16. doi: https://doi.org/10.1016/S0140-6736(20)30314-7.

Article  CAS  PubMed  Google Scholar 

Wondergem M, van der Zant FM, Broos WAM, Roeleveld TA, Donker R, Ten Oever D, et al. (18)F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy. Eur J Nucl Med Mol Imaging. 2021;48(2):521-31. doi: https://doi.org/10.1007/s00259-020-04782-2.

Article  CAS  PubMed  Google Scholar 

Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387-95. doi: https://doi.org/10.1016/j.crad.2007.05.022.

Article  CAS  PubMed  Google Scholar 

Woo S, Suh CH, Kim SY, Cho JY, Kim SH. The Diagnostic Performance of MRI for Detection of Lymph Node Metastasis in Bladder and Prostate Cancer: An Updated Systematic Review and Diagnostic Meta-Analysis. AJR Am J Roentgenol. 2018;210(3):W95-W109. doi: https://doi.org/10.2214/AJR.17.18481.

Article  PubMed  Google Scholar 

Wang R, Shen G, Yang R, Ma X, Tian R. (68)Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis. Eur J Radiol. 2020;130:109131. doi: https://doi.org/10.1016/j.ejrad.2020.109131.

Roach M, 3rd, Hanks G, Thames H, Jr., Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-74. doi: https://doi.org/10.1016/j.ijrobp.2006.04.029.

Article  PubMed  Google Scholar 

Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540-5. doi: https://doi.org/10.1016/j.juro.2006.10.097.

Article  CAS  PubMed  Google Scholar 

Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;68(3):593-8. doi: https://doi.org/10.1016/j.urology.2006.03.075.

Article  PubMed  Google Scholar 

Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol. 2014;66(3):479-86. doi: https://doi.org/10.1016/j.eururo.2013.11.045.

Article  CAS  PubMed  Go